Biology and novel treatment options for XLA, the most common monogenetic immunodeficiency in man
- 28 May 2011
- journal article
- Published by Taylor & Francis Ltd in Emerging Therapeutic Targets
- Vol. 15 (8), 1003-1021
- https://doi.org/10.1517/14728222.2011.585971
Abstract
Introduction: X-linked agammaglobulinemia (XLA) is the most common primary immunodeficiency in man, and is caused by a single genetic defect. Inactivating mutations in the Bruton's tyrosine kinase (BTK) gene are invariably the cause of XLA,. XLA is characterized by a differentiation arrest at the pre-B cell stage, the absence of immunoglobulins and recurrent bacterial infections, making it an insidious disease that gradually disables the patient, and can result in death due to chronic lung disease. Current treatment involves prophylactic antibiotics and immunoglobulin infusions, which are non-curative. This disease is a good candidate for curative hematopoietic stem cell (HSC)-based gene therapy, which could correct the B cell and myeloid deficiencies. Areas covered: This paper reviews the basic biology of BTK in B cell development, the clinical features of XLA, and the possibilities of gene therapy for XLA, covering the literature from 1995 to 2010. Expert opinion: Work from various laboratories demonstrates the feasibility of using gene-corrected HSCs to complement the immune defects of Btk-deficiency in mice. We propose that it is timely to start clinical programs to develop stem cell based therapy for XLA, using gene-corrected autologous HSC.Keywords
This publication has 102 references indexed in Scilit:
- MicroRNAs Prevent the Generation of Autoreactive AntibodiesImmunity, 2010
- Stem-Cell Gene Therapy for the Wiskott–Aldrich SyndromeThe New England Journal of Medicine, 2010
- Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemiaNature, 2010
- Role of STAT5 in controlling cell survival and immunoglobulin gene recombination during pro-B cell developmentNature Immunology, 2009
- Btk regulates localization, in vivo activation, and class switching of anti-DNA B cellsMolecular Immunology, 2008
- Sola dosis facit venenum. Leukemia in gene therapy trials: a question of vectors, inserts and dosage?Leukemia, 2008
- Interaction of Btk and Akt in B cell signalingBiochemical and Biophysical Research Communications, 2002
- Defective B cell development and function in Btk-deficient miceImmunity, 1995
- Carrier detection in typical and atypical X-linked agammaglobulinemiaThe Journal of Pediatrics, 1988
- Expression of the Gene Defect in X-Linked AgammaglobulinemiaThe New England Journal of Medicine, 1986